{
    "score": [
        0.8888888888888888
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "uniqure nv svp sells $ 118,042.32 in stock ."
    ],
    "id": "625430.train",
    "article": [
        "uniqure nv svp maria e. cantor sold 5,864 shares of the business 's stock in a transaction on wednesday , january 3rd . the shares were sold at an average price of $ 20.13 , for a total transaction of $ 118,042.32 . the sale was disclosed in a document filed with the securities & exchange commission , which is available through this link . uniqure nv traded down $ 0.34 during trading hours on wednesday , reaching $ 19.82 . 538,165 shares of the company 's stock were exchanged , compared to its average volume of 443,600 . the stock has a market cap of $ 610.46 , a price-to-earnings ratio of -7.59 and a beta of 0.72 . ",
        "the company has a debt-to-equity ratio of 0.73 , a quick ratio of 3.64 and a current ratio of 3.64 . uniqure nv has a 52 week low of $ 4.72 and a 52 week high of $ 21.35 . a number of large investors have recently added to or reduced their stakes in qure . mangrove partners lifted its holdings in uniqure by 167.4 % in the 3rd quarter . mangrove partners now owns 106,634 shares of the biotechnology company 's stock valued at $ 1,024,000 after purchasing an additional 66,763 shares in the last quarter . fmr llc lifted its holdings in uniqure by 4.1 % in the 2nd quarter . ",
        "fmr llc now owns 1,560,113 shares of the biotechnology company 's stock valued at $ 9,656,000 after purchasing an additional 61,650 shares in the last quarter . oxford asset management llp acquired a new position in shares of uniqure during the 3rd quarter valued at about $ 399,000 . finally , jpmorgan chase & co. . increased its stake in shares of uniqure by 33.5 % during the 2nd quarter . jpmorgan chase & co. . now owns 58,481 shares of the biotechnology company 's stock valued at $ 362,000 after acquiring an additional 14,659 shares during the last quarter . ",
        "institutional investors own 24.87 % of the company 's stock . several equities analysts have issued reports on qure shares . zacks investment research cut shares of uniqure from a `` hold '' rating to a `` sell '' rating in a research note on wednesday , october 18th . leerink swann boosted their price objective on shares of uniqure from $ 17.00 to $ 19.00 and gave the company an `` outperform '' rating in a research note on friday , october 20th . evercore isi initiated coverage on shares of uniqure in a research report on tuesday , november 7th . ",
        "they set an `` outperform '' rating and a $ 22.00 target price on the stock . oppenheimer restated a `` hold '' rating on shares of uniqure in a research report on friday , november 24th . finally , hc wainwright initiated coverage on shares of uniqure in a research report on friday , december 1st . they set a `` buy '' rating and a $ 28.00 target price on the stock . four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company 's stock . the stock has a consensus rating of `` buy '' and an average target price of $ 20.00 . ",
        "copyright violation warning : this news story was originally published by american banking news and is the sole property of of american banking news . if you are accessing this news story on another site , it was stolen and republished in violation of united states and international copyright law . the original version of this news story can be read at company profileuniqure nv is a gene therapy company based in the netherlands . the company is engaged in the discovery , development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases . ",
        "the company advances a focused pipeline of gene therapies that are developed both internally and through partnerships . receive news & ratings for uniqure daily - enter your email address below to receive a concise daily summary of the latest news and analysts ' ratings for uniqure and related companies with marketbeat . com 's free daily email newsletter .   "
    ]
}